0 Items
Select Page

Neisseria gonorrhoeae

Gonorrhoea is the second most common bacterial sexually-transmitted infection in the UK, after chlamydia. In 2017, more than 44,500 people were diagnosed with gonorrhoea in England, with most cases affecting young men and women under the age of 25.

The Native Antigen Company develop and manufacture preparations of N. gonorrhoeae antigen as controls for diagnostic assays.

Neisseria gonorrhoeae Background

Neisseria gonorrhoeae (NG) is a gram-negative diplococcus. It is an obligate human pathogen that infects urogenital epithelia, causing the sexually transmitted disease gonorrhoea. N. gonorrhoeae infects both men and women and is primarily transmitted through close sexual contact with an infected individual. N. gonorrhoeae can also be transmitted to neonates, born to infected mothers, during delivery.

Approximately 78 million people contract N. gonorrhoeae infection each year and cases are reported to be increasing (WHO). The common sites for gonococcal infection are the urethra in men and the uterine cervix in women. However, anal and oral sex can also cause infection in the anus and throat. Gonorrhoea is often described as an uncomplicated disease, which is asymptomatic in most females and some males. If left undiagnosed and untreated, infection in women may affect the upper genital tract causing pelvic inflammatory disease and fertility problems. Neonates infected with N. gonorrhoeae can develop rhinitis, vaginitis or urethritis. In severe cases, infected infants may develop ophthalmia neonatorum, a form of conjunctivitis, and sepsis (CDC).

Although Leistikow and Löffler first cultivated the gonococcus in 1882, N. gonorrhoeae is an ancient disease that has, in recent years, been treated successfully with antibiotics. However, N. gonorrhoeae is now reported to be resistant to most antibiotics, with the exception of cephalosporin and is becoming a major global health concern (Unemoa, M.).

References

  1. World Health Organization: Antibiotic resistant gonorrhoea on the rise, new drugs needed
  2. Centres for Disease Control and Prevention: Gonoccocal infections
  3. Unemoa, M and Shafer, W.M. (2014). Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clin Microbiol Rev. Jul; 27(3): 587–613

Neisseria gonorrhoeae Antigens

We prepare Neisseria antigen from a preparation of whole bacteria cultured in vitro, followed by homogenisation and sonication. This produces an antigen preparation especially well-suited for use in immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 4 =

Live Customer Feedback

Join our mailing list

* indicates required